The poor response of existing treatnnent options for unresectable pancreatic cancer is the result of a subset of cancer cells exhibiting chemoresistance. Evidence has shown that the capacity of a tumor to grow and propagate is dependent on this small subset of cells, identified as pancreatic cancer stem (or stem-like) cells (CSCs). Due to their vital role in tumor maintenance and the formation of metastases, CSCs are integral targets to treat pancreatic cancer, as current therapeutic regimens cannot effectively treat this cell population because of its intrinsically resistant nature. Adenovirus (Ad)-based oncolytic viruses have unique advantages for targeting and eradicating pancreatic CSCs along with inclusively targeting the general pancreatic cancer cell population and thereby represent a promising novel therapeutic strategy. Ad replication specificity can be achieved by placing viral replication genes under the control of tumor-specific promoters, thereby generating conditionally replicative adenoviruses (CRAds). The keys to developing a pancreatic cancer CRAd that inclusively targets CSCs are: 1) effective transduction and 2) replication specificity of pancreatic cancer cells and CSCs. We have developed innovative strategies and breakthrough technologies which can be rapidly applied for designing such CRAds. Our advanced infectivity enhancement strategies allow efficient transduction of pancreatic cancer cells and CSCs. To confer replication specificity, we have developed the CXCR4 promoter as a CRAd replication control element. CXCR4 expression Is a signature of pancreatic cancer and CSCs. SA 1: To construct infectivity-enhanced, CXCR4 promoter controlled CRAds for pancreatic cancer, inclusively targeting pancreatic CSCs. SA 2: To validate the efficacy of CRAds with in vitro models of chemoresistant pancreatic CSCs. SA 3: To demonstrate efficacious targeting and replication of CXCR4 CRAds with in vivo models of pancreatic cancer. SA 4: To validate the efficacy and specificity of pancreatic CSC-targeted CRAds with primary CSCs derived from human patient tumors. Development of an effective therapy for the advanced pancreatic cancer Is predicated on efficiently targeting and eradicating pancreatic CSCs, which represent the chemoresistant nature of this disease. The strategy proposed herein, of exploiting CRAd agents based on the CXCR4 axis to inclusively target pancreatic CSCs offers a promising treatment approach. On the basis of these studies, we will thus understand the direct utility of our novel system for clinical application and will facilitate a rapid clinical translation. We will submit an IND application concurrently with this proposal to rapidly translate the agents herein for clinical trial.

Public Health Relevance

Development of an effective therapy for the treatment of advanced pancreatic cancer is predicated on efficiently targeting and eradicating pancreatic cancer stem cells (CSCs), which represent the chemoresistant nature of this disease. Recent advances in adenovirus (Ad)-based oncolytic virus design allow the application of Ad vectors as a therapeutic strategy to efficiently target and eradicate pancreatic nSCs therehv imnrnvina the efficacv nf nannreatic cancer treatment.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-GRB-I)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Alabama Birmingham
United States
Zip Code
Ramesh, Jayapal; Kim, Hwasoon; Reddy, Kartika et al. (2014) Impact of pancreatic stent caliber on post-endoscopic retrograde cholangiopancreatogram pancreatitis rates in patients with confirmed sphincter of Oddi dysfunction. J Gastroenterol Hepatol 29:1563-7
Kaliberov, S A; Kaliberova, L N; Buchsbaum, D J et al. (2014) Experimental virotherapy of chemoresistant pancreatic carcinoma using infectivity-enhanced fiber-mosaic oncolytic adenovirus. Cancer Gene Ther 21:264-74
Bohrer, Laura R; Chuntova, Pavlina; Bade, Lindsey K et al. (2014) Activation of the FGFR-STAT3 pathway in breast cancer cells induces a hyaluronan-rich microenvironment that licenses tumor formation. Cancer Res 74:374-86
Dmitriev, Igor P; Kashentseva, Elena A; Kim, Kenneth H et al. (2014) Monitoring of biodistribution and persistence of conditionally replicative adenovirus in a murine model of ovarian cancer using capsid-incorporated mCherry and expression of human somatostatin receptor subtype 2 gene. Mol Imaging 13:
Chio, Iok In Christine; Yordanov, Georgi; Tuveson, David (2014) MAX-ing out MYC: a novel small molecule inhibitor against MYC-dependent tumors. J Natl Cancer Inst 106:
Auer, H; Mobley, J A; Ayers, L W et al. (2014) The effects of frozen tissue storage conditions on the integrity of RNA and protein. Biotech Histochem 89:518-28
Hébert-Magee, Shantel; Varadarajulu, Shyam; Frost, Andra R et al. (2014) Primary pancreatic leiomyosarcoma: a rare diagnosis obtained by EUS-FNA cytology. Gastrointest Endosc 80:361-2
Kim, Hyunki; Rigell, Christopher J; Zhai, Guihua et al. (2014) Antagonistic effects of anti-EMMPRIN antibody when combined with chemotherapy against hypovascular pancreatic cancers. Mol Imaging Biol 16:85-94
Reddy, Kartika; Hooper, Kari; Frost, Andra et al. (2014) Intraductal papillary carcinoma of common bile duct diagnosed by endoscopic ultrasound-guided fine-needle aspiration. Endoscopy 46 Suppl 1 UCTN:E248-9
Desai, Leena P; Zhou, Yong; Estrada, Aida V et al. (2014) Negative regulation of NADPH oxidase 4 by hydrogen peroxide-inducible clone 5 (Hic-5) protein. J Biol Chem 289:18270-8

Showing the most recent 10 out of 53 publications